Bacainn Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 9

Employees

  • Latest Deal Type
  • M&A

Bacainn Therapeutics General Information

Description

Developer of novel cell therapies designed to address uncontrolled inflammation driven by dysregulated immune cells. The company's therapies are focused on the discovery and development of novel immune cell-modulating drugs to control ulcerative colitis, diabetic wound healing, respiratory inflammation, and oncology, enabling medical professionals to investigate the use of these drugs and to bring damaging inflammation under control.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 530 Virginia Road
  • Suite 300
  • Concord, MA 01742
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 530 Virginia Road
  • Suite 300
  • Concord, MA 01742
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bacainn Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 10-Mar-2022 Completed Generating Revenue
1. Early Stage VC Completed Startup
To view Bacainn Therapeutics’s complete valuation and funding history, request access »

Bacainn Therapeutics Patents

Bacainn Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4611734-A1 Probenecid compounds for the treatment of inflammasome-mediated dermatological conditions Pending 04-Nov-2022
US-20260176232-A1 Probenecid compounds for the treatment of inflammasome-mediated dermatological conditions Pending 04-Nov-2022
US-20240277798-A1 Cyclosporine compositions and methods of use Pending 20-Apr-2021
AU-2021303146-A1 Probenecid compounds for the treatment of inflammasome-mediated lung disease Pending 29-Jun-2020
CA-3184151-A1 Probenecid compounds for the treatment of inflammasome-mediated lung disease Pending 29-Jun-2020 C07D211/34
To view Bacainn Therapeutics’s complete patent history, request access »

Bacainn Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bacainn Therapeutics Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Morningside Group Venture Capital Minority
To view Bacainn Therapeutics’s complete investors history, request access »

Bacainn Therapeutics Acquisitions (1)

Bacainn Therapeutics’s most recent deal was a Merger of Equals with Adiso Therapeutics. The deal was made on 10-Mar-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Adiso Therapeutics 10-Mar-2022 Merger of Equals Drug Discovery
To view Bacainn Therapeutics’s complete acquisitions history, request access »

Bacainn Therapeutics FAQs

  • When was Bacainn Therapeutics founded?

    Bacainn Therapeutics was founded in 2017.

  • Where is Bacainn Therapeutics headquartered?

    Bacainn Therapeutics is headquartered in Concord, MA.

  • What is the size of Bacainn Therapeutics?

    Bacainn Therapeutics has 9 total employees.

  • What industry is Bacainn Therapeutics in?

    Bacainn Therapeutics’s primary industry is Drug Discovery.

  • Is Bacainn Therapeutics a private or public company?

    Bacainn Therapeutics is a Private company.

  • What is Bacainn Therapeutics’s current revenue?

    The current revenue for Bacainn Therapeutics is .

  • Who are Bacainn Therapeutics’s investors?

    Morningside Group has invested in Bacainn Therapeutics.

  • When was Bacainn Therapeutics acquired?

    Bacainn Therapeutics was acquired on 10-Mar-2022.

  • Who acquired Bacainn Therapeutics?

    Bacainn Therapeutics was acquired by Adiso Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process